Evidence map›Paper›PMID 40282412›Full record

ArticleGenes2025

Association of ABC Efflux Transporter Genetic Variants and Adverse Drug Reactions and Survival in Patients with Non-Small Lung Cancer.

Cecilia Souto Seguin, Giovana Fernanda Santos Fidelis, Carolina Dagli-Hernandez, Pedro Eduardo Nascimento Silva Vasconcelos, Mariana Vieira Morau, Yasmim Gabriele Matos, Maurício Wesley Perroud, Eder de Carvalho Pincinato, Patricia Moriel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cecilia Souto SeguinSchool of Medical Sciences, Universidade Estadual de Campinas, Campinas 13083894, Brazil.
Giovana Fernanda Santos FidelisSchool of Medical Sciences, Universidade Estadual de Campinas, Campinas 13083894, Brazil.ORCID 0000-0002-9867-389X
Carolina Dagli-HernandezFaculty of Pharmaceutical Sciences, Universidade Estadual de Campinas, Campinas 13083970, Brazil.ORCID 0000-0003-2109-9399
Pedro Eduardo Nascimento Silva VasconcelosSchool of Medical Sciences, Universidade Estadual de Campinas, Campinas 13083894, Brazil.ORCID 0000-0001-8428-4124
Mariana Vieira MorauSchool of Medical Sciences, Universidade Estadual de Campinas, Campinas 13083894, Brazil.ORCID 0000-0002-7423-1413
Yasmim Gabriele MatosSchool of Medical Sciences, Universidade Estadual de Campinas, Campinas 13083894, Brazil.ORCID 0000-0002-6729-5216
Maurício Wesley PerroudSchool of Medical Sciences, Universidade Estadual de Campinas, Campinas 13083894, Brazil.ORCID 0000-0001-5984-9947
Eder de Carvalho PincinatoSchool of Medical Sciences, Universidade Estadual de Campinas, Campinas 13083894, Brazil.
Patricia MorielSchool of Medical Sciences, Universidade Estadual de Campinas, Campinas 13083894, Brazil.ORCID 0000-0002-4927-7022

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/06703-7Fundação de Amparo à Pesquisa do Estado de São Paulo 2023/06280-7Fundação de Amparo à Pesquisa do Estado de São Paulo 2023/16093-0National Council for Scientific and Technological Development 14030/2019-4National Council for Scientific and Technological Development 444090/2023Pharmaceutical Security Nucleus Project 895688/2019
6 · The paper itself

Abstract

BACKGROUND/

objectivesLung cancer has a high mortality rate worldwide, with non-small cell lung cancer (NSCLC) being the most prevalent. Carboplatin and paclitaxel are key treatments for NSCLC; however, adverse drug reactions (ADRs) pose significant challenges. This study examined the impact of genetic variations in

methodsVariants were identified using RT-PCR, and ADRs classified according to the Common Toxicity Criteria for Adverse Events, Version 4.03.

resultsThe

conclusionsThe data suggest that

Indexed as

ATP-Binding Cassette, Sub-Family C ProteinsCarcinoma, Non-Small-Cell LungDrug-Related Side Effects and Adverse ReactionsLung NeoplasmsAdultAgedATP Binding Cassette Transporter, Subfamily BCarboplatinFemaleGenotypeHumansMaleMiddle AgedMultidrug Resistance-Associated Protein 2PaclitaxelPolymorphism, Single NucleotideABCB1 protein, humanABCC2 protein, humanATP-Binding Cassette, Sub-Family C ProteinsATP Binding Cassette Transporter, Subfamily BCarboplatinMultidrug Resistance-Associated Protein 2PaclitaxelABC transportergenetic variantslung cancer

Identifiers

PMID40282412
PMCPMC12026804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.